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1 |  BACKGROUND
Nontraumatic fat embolism syndrome (ntFES) is an un-
der-recognized yet well-known complication of bone mar-
row infarction/necrosis (BMN) occurring in patients with 
sickle cell disease (SCD) with an estimated incidence of 
0.3%-37%.1 Classic triad includes respiratory failure, neu-
rological deficits, and a petechial rash. Fat embolism syn-
drome (FES) remains a clinical diagnosis. Its nonspecific 
manifestations require a heightened index of suspicion. 
Prompt recognition and treatment are vital to reduce mortal-
ity and limit disability.
2 |  OBJECTIVE
To report a case of ntFES manifested by multisystem 
organ failure in an elderly patient who attained neurologic 
recovery.
3 |  CASE REPORT
A 75-year-old woman with HbSC disease, right hip avascular 
necrosis postreplacement, Chiari I malformation, and essen-
tial hypertension initially presented with one day of “deep” 
bilateral thigh pain progressing to diffuse body pain and chest 
pain. She has a history of infrequent sickle cell pain crises, 
last occurring several years ago. She had no history of recent 
travel and was born in the United States.
The patient was hospitalized for suspected vaso-occlu-
sive crisis. On initial examination, she was communicative 
yet uncomfortable and distressed, afebrile, and hemodynam-
ically stable. She exhibited significant bilateral thigh pain, 
severely restricting the range of motion. Admission laborato-
ries (see Table 1) were largely unremarkable except for mild 
leukocytosis.
Within 36 hours of admission, she rapidly declined with 
multi-organ dysfunction, as evidenced by progressive en-
cephalopathy, respiratory failure, troponinemia, acute kidney 
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Abstract
Cerebral fat embolism syndrome is an under-recognized yet well-known compli-
cation of bone marrow necrosis occurring in patients with sickle cell disease. We 
highlight a case manifested by multisystem organ failure in an elderly patient who at-
tained neurologic recovery with prompt initiation of hematology consultation, RBC 
exchange, and supportive measures.
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injury, bicytopenia, transaminitis, and lactic acidosis. She 
would later become febrile (up to 39.6°C), tachycardic, tachy-
pneic, hypoxic, and hypertensive. Her symptoms progressed 
to unresponsiveness, respiratory distress, Cheyne-Stokes 
breathing, and eventually respiratory failure requiring urgent 
intubation. Initial head tomography and angiography were 
unrevealing. Chest imaging revealed small scattered focal in-
filtrates, mild pulmonary edema, and small-volume bilateral 
pleural effusions. She was started on broad-spectrum antibi-
otics for a presumed infection. Brain MRI showed extensive 
multiple microhemorrhages across the neuroparenchyma in 
a “starfield” pattern classic for cerebral FES (see Figure 1).
The combination of mental status changes, given MRI 
findings above, scattered pulmonary infiltrates on chest im-
aging, and leukoerythroblastic picture observed on peripheral 
smear, in a patient with HbSC disease, strongly supported the 
diagnosis of ntFES. The patient was transferred for urgent 
treatment via red blood cell exchange. Additional supportive 
measures were administered to limit the extent of morbid-
ity including oxygenation/ventilation, volume resuscitation 
(with crystalloid and albumin—theoretically binds free fatty 
acids, FFAs, which are implicated in the pathophysiology of 
FES), blood products, and nutrition.2
Twenty-four hours after exchange transfusion, her GCS 
was 3/10T. She slowly and erratically recovered to GCS of 
10/10T in 14 days. However, she remained profoundly paretic 
and required ventilation and assisted feeding via tracheostomy 
and gastrostomy, respectively. She was discharged to a spe-
cialty long-term acute care hospital (LTAC) after 18 days of 
treatment in the ICU. She remained in LTAC for an additional 
45 days, and significant improvements were noted across all 
cognitive domains. She was weaned from the ventilator and 
decannulated on day 60. She was transferred to an acute re-
habilitation facility (ARF) on day 66. Following treatment, 
she exhibited 4+/5 strength in all extremities, fluent speech, 
and ADL independence. She was discharged home 90 days 
following her initial presentation with ntFES.
4 |  DISCUSSION
There exists a limited number of reports of cerebral FES 
in the setting of underlying SCD within the medical litera-
ture.3,4 Reports of successful treatment of cerebral FES in 
SCD are even rarer.3,5 This is an important clinical entity 
for healthcare personnel to recognize as (a) it can easily be 
misdiagnosed as other mimicking pathologies such as sepsis, 
vasculitis, hypoxic-ischemic encephalopathy, acute hemor-
rhagic leukoencephalitis, or thrombotic microangiopathies,6,7 
and (b) early intervention reduces morbidity and mortality.
The first reported case of systemic/cerebral FES comes 
from Wade and Stevenson in 1941 where they share the story 
of a 49-year-old Mediterranean woman with SCD whose 
presentation is strikingly similar to our own patient.8 In many 
instances, significant localized or diffuse pain(s)/vaso-occlu-
sive crises may be the initial presenting symptom. This can 
be associated with or escalate to systemic signs of illness. 
These include, but are not limited to, markedly elevated fe-
vers, tachycardia, and tachypnea. One may also observe a 
rapid decrease in the patient’s level of consciousness.7 The 
hallmark clinical triad of respiratory failure, neurologic defi-
cits/failure, and petechial rash are foreboding warning signs 
of pending clinical deterioration via “showering” of fat em-
boli within the microvasculature.8
The diagnosis of ntFES is clinical and should be made 
within the appropriate clinical setting. Though scoring sys-
tems exist to aid in its diagnosis, its nonspecific manifes-
tations require a heightened index of suspicion. Clinical, 
laboratory, and imaging findings can further aid in the di-
agnosis of FES. Laboratory findings are consistent with 
systemic inflammation and signs of multisystem end-or-
gan damage.3 There is often a leukoerythroblastic picture 
observed on peripheral smear.3 Chest radiography often 
shows diffuse bilateral infiltrates.2,9 Depending on the time 
course, susceptibility-weighted imaging may reveal diffuse 
micro-punctate hemorrhages in a “starfield pattern.” This 
finding is pathognomonic for acute cerebral microinfarcts 
and reflects microbleeds in the splenium and subcortical 
locations.4,6 This finding correlates with neurologic failure 
requiring urgent endotracheal intubation. It also reflects the 
underlying inflammatory response to circulating adipose tis-
sue within the microcirculation.
The pathogenesis of FES, in SCD, is unknown.9 Several 
mechanical, biochemical, and immunological hypotheses have 
been suggested.2,3,9 One of them suggests that an unknown 
trigger (virus, immunologic reaction, or increased viscosity in 
HbSC patients due to higher hemoglobin) causes BMN which 
in turn causes fat embolism and hypoxia. Both mechanical and 
biochemical theories have been proposed to explain its patho-
physiology—that is, mechanical obstruction by fat droplets 
within microvasculature, and degradation of embolized drop-
lets into FFAs generating toxic metabolites with downstream 
pro-inflammatory effects.2 The resulting hypoxia perpetuates 
the cycle by increasing sickling, leading to further down-
stream vaso-occlusion/infarction ultimately increasing BMN.
When suspected, treatment is aimed toward the underly-
ing cause as well as the pathophysiologic basis of FES. The 
time of onset for ntFES is usually 24-72  hours and mani-
fests as central nervous system abnormalities, respiratory 
insufficiency, petechial rash, hemodynamic instability, and 
fever.4,8 Urgent hematology consultation should be obtained. 
Treatment is primarily supportive. In the 58 cases analyzed 
by Tsitsikas et al., patients receiving exchange transfusion, 
simple transfusion, and supportive care alone had mortal-
ity rates of 29%, 61%, and 91%, respectively, indicating de-
creased mortality with timely initiation of therapy.3
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T A B L E  1  Laboratory values obtained during the acute phase of illness and treatment
Variable
Reference Time after initial inpatient admissiona 
Range 0 h 18 h 36 h 2 d 2.5 d 3 d 5 d 21 d 66 d 83 d
Leukocyte count, 103 
cells/mm3
3.6-10.6 12.1 14.3 20.8 - 14.2 12.8 11.6 8.9 5.3 3.7
Hemoglobin (Hgb), 
g/dL
12-15 10.2 8.2 6.7 - 5.9 6.1 9.7b 7.9 8.6 9.3
Platelet count, 103 
cells/mm3
150-450 180 55 29 - 43 32 88 257 166 193
Reticulocyte count 
Abs, 103 cells/mm3
21-115 118.7 - - 85.4 - - - - -
Protime, seconds 9-12 - 11.6 - 15.3 - 14.8 - - -
INR 0.8-1.2 - 1.2 - 1.4 - 1.35 - - -
aPTT, s 23.4-38.0 - - 30.9 - 31.0 - - -
Fibrinogen, mg/dL 170-399 - 460 442 - 510 - - -
Arterial blood gas
pH 7.35-7.45 - 7.39 7.55 7.48 - - - - - -
pCO2, mmHg 35-48 - 47 25 29 - - - - - -
pO2, mmHg 83-108 - 40
c 55 229 - - - - - -




136-145 143 139 137 137 144 145 152 140 139 141
Potassium level, 
mmol/L
3.5-5.5 3.5 4.3 4.2 4.4 4.0 3.9 3.7 4.0 3.8 3.4
Chloride level, 
mmol/L
98-107 109 104 104 106 111 111 115 108 108 107
Bicarb level, mmol/L 21-32 25 25 25 15 24 24 24 24 25 24
BUN level, mg/dL 7-18 22 19 25 20 41 46 40 19 10 5
Creatinine, mg/dL 0.51-0.95 0.77 0.78 0.98 0.67 1.28 1.39 1.21 0.63 0.60 0.63
Glucose, mg/dL 74-106 132 125 127 106 140 129 140 101 83 86
Calcium, mg/dL 8.5-10.1 8.3 8.4 7.9 6.8 8.0 8.3 8.3 8.0 9.0 9.2
Total protein, g/dL 6.4-8.2 - - 6.0 3.3 5.4 - 5.6 - - -
Albumin, g/dL 3.4-5.0 - - 2.8 1.5 3.3 - 3.2 - - -
Total bilirubin mg/
dL
0.2-1.0 - - 1.0 0.7 0.9 - 1.1 - - -
ALP, IU/L 45-117 - - 338 167 182 - 124 - - -
AST, U/L 15-37 - - 188 104 88 - 52 - - -
ALT, IU/L 12-78 - - 116 59 58 - 41 - - -
Lactate, mmol/L 0.4-2.0 - - 2 11 2.7 1.3 - - - -
Troponin, ng/mL 0.00-0.04 <0.02 - 1.88 1.18 1.23 - - - - -
D-dimer, mcg FEU/
mL
0.00-0.49 - - - 35.20 - - - - -
, ng/dL <292 - - - - 13 292 12 060 25 703 5280 - -
Ferritin, ng/mL 10-291 - - - >16 500 - - - - - -
, ng/mL 10-106 - - - - 25 110 - - - - -
hs CRP, mg/dL <0.30 0.56 - - 13.7 - - - - - -
(Continues)
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5 |  SUMMARY
Sickle cell disease, particularly HbSC disease, has been impli-
cated as a rare precipitant for FES—a potentially devastating 
syndrome resulting from BMN secondary to an inciting event 
(e.g., vaso-occlusion).4,10 Few cases of FES in HbSC disease 
have been published.1,3-5,7,9,10 Most present with pulmonary 
symptoms. While this eventually results in neurologic dysfunc-
tion, fat embolism in HbSC disease presenting as progressive 
nonresolving encephalopathy is rare. Cases presenting pri-
marily with encephalopathy usually carry a worse long-term 
prognosis.10Acute presentation with confounders such as en-
cephalopathy, troponin elevation, and cytopenias can lead to 
time-consuming testing. Clinicians must have a high index of 
suspicion in patients with SCD who develop acute encephalop-
athy. Hematology consultation, RBC exchange, and support-
ive measures must be initiated promptly to limit morbidity and 
mortality, to preserve functionality, and to promote improved 




Reference Time after initial inpatient admissiona 
Range 0 h 18 h 36 h 2 d 2.5 d 3 d 5 d 21 d 66 d 83 d
Sed Rate, mm/h 0-30 - - 9 23 - - - - - -
Ammonia 11-32 - - 12 - - - - - - -
Prolactin 2.8-29.2 - - 9.7 - - - - - - -
Creatine Kinase, U/L 26-192 46 - - - - - - - - -
LDH, Units/L 84-246 - - - 1707 2615 - 1530 - - -
Haptoglobin, mg/dL 30-200 - - - 14 44 - - - - -
TSH, mcU/mL 0.400-4.200 - - - - - - 1.142 - - -
Glasgow Coma Scale score - - - - 3/10T - - 10/10T 15/15 15/15
Note: Notable time points: 0 h = Admission, 36 h = Significant clinical deterioration, 2 d = Intubation for airway protection, transferred to tertiary institution, 2.5 
d = RBC exchange transfusion initiated, 21 d = Transfer to LTAC, 66 d = Transfer to ARF, 83 d = Prior to discharge.
Significant abnormal laboratory values are depicted in bold. Laboratory testing revealed precipitous drops in hemoglobin (from baseline of 10 g/dL to nadir 5.4 g/dL, 
not shown) and platelets and increases in troponin (peak of 1.94 ng/mL not shown), lactate (12 mmol/L not shown), D-dimer, fibrinogen, ferritin, LDH, C-reactive 
protein, and A-a gradient. Initial acid-base analysis revealed triple acid-base disorder with respiratory alkalosis, anion-gap metabolic acidosis due to elevated lactate, 
and non-anion-gap metabolic acidosis. Prolactin was obtained during patient’s workup for unresponsiveness and consideration for seizure. Of note, peripheral smear 
was consistent with a leukoerythroblastic picture, showing marked anemia with microcytosis, numerous target cells, frequent nucleated RBCs and few schistocytes, 
and mature WBC morphology with leukocytosis and neutrophilia, further supporting diagnosis of fat embolism syndrome.
Hemoglobin Electrophoresis Studies (not shown): Historical, Patient’s Baseline (2014): Relative percentages of HgbA, HgbA2, HgbC, HgbF, and HgbS were 0%, 
0%, 48%, 0%, and 52%, respectively. For this case, no electrophoresis studies were done prior to first exchange. Following initial RBC Exchange transfusion: Relative 
corresponding values were 28.8%, 3.6%, 28.4%, 5.1%, and 34.1%, respectively. Post-initial transfusion, corresponding values were 91.4%, 2.4%, 2.7%, 0.4%, and 3.1%, 
respectively. Two weeks after initiation of multiple transfusions, corresponding values were 76.3%, 3.2%, 9.3%, 0.4%, and 10.8%, respectively. Reference values: 
HgbA: 94.0%-98.5%, HgbA2: 1.5%-3.5%, HgbC: nil, HgbF: 0.0%-2.0%, HgbS: nil.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; d, 
days; FEU, fibrinogen-equivalent units; h, hours; Hgb, hemoglobin; hs CRP, high-sensitivity C-reactive protein; INR, international normalized ratio; LDH, lactate 
dehydrogenase; TSH, thyroid-stimulating hormone.
aFor ease of reference, the time points listed are near approximations. 
bAfter exchange transfusion. 
cThis partial pressure measurement is from venous blood gas. 
T A B L E  1  (Continued)
F I G U R E  1  Susceptibility-weighted imaging which reveals 
diffuse punctate microhemorrhages throughout the neuroparenchyma 
in the “starfield” pattern consistent with cerebral fat embolism
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